Interleukin 17 (IL-17) is an important cytokine that can induce tissue inflammation and is involved in the pathogenesis of numerous autoimmune diseases. However, the regulation of its signaling transduction has not been well described. In this study, we report that thousand and one kinase 1 (TAOK1) functions as a negative regulator of IL-17-mediated signal transduction and inflammation. TAOK1 knockdown promotes IL-17-induced cytokine and chemokine expression and the activation of mitogen-activated protein kinases and nuclear factor-κB. We further demonstrate that TAOK1 interacts with IL-17 receptor A (IL-17RA) independent of its kinase activity, and TAOK1 dose-dependently prevents the formation of the IL-17R-Act1 (nuclear factor activator 1, also known as tumor necrosis factor receptor-associated factor 3 interacting protein 2) complex. Consistent with this, TAOK1 deficiency exacerbates colitis in the 2,4,6-trinitrobenzenesulfonic acid)-induced experimental model of inflammatory bowel disease, likely by its promotion of the IL-17-mediated signaling pathway. TAOK1 expression is decreased in the colons of ulcerative colitis patients. In conclusion, these findings suggest that TAOK1 is involved in the development of IL-17-related autoimmune disorders.
INTRODUCTION
The interleukin 17 (IL-17) family consists of six molecules, namely, IL-17A to IL-17F. IL-17 (also named IL-17A) is a fundamental member and the most investigated cytokine in this family. 1 IL-17A is a hallmark cytokine of T helper type 17 (Th17) cells and can be produced by many innate immune cells, 2 including γδT, iNKT and NK cells. [3] [4] [5] As a proinflammatory cytokine, IL-17 exerts its effects by promoting the expression of matrix metalloproteinases and proinflammatory genes such as IL-6, CXC-chemokine ligand 1 (CXCL1), CXCL2, CC-chemokine ligand 20 (CCL20) and colony-stimulating factor 3 (CSF3), which can result in neutrophil infiltration and inflammation in tissue. 1 Dysregulation of IL-17 signaling may lead to autoimmune diseases such as inflammatory bowel disease (IBD) and Sjögren's syndrome. 6, 7 The IL-17 receptor (IL-17R) family has been described as consisting of five subunits, from IL-17 receptor A (IL-17RA) to IL-17RE. IL-17 binds a receptor complex of IL-17RA and IL-17RC subunits. Targeting IL-17RA can block IL-17-mediated proinflammatory pathways. 6, 8 The binding of IL-17 to the IL-17RA-IL-17RC complex results in recruitment of the ubiquitin ligase adaptor protein Act1. Act1 further recruits tumor necrosis factor receptor-associated factor 6 (TRAF6) to induce the activation of nuclear factor-κB (NF-κB) and mitogenactivated protein kinase (MAPK) pathways and the upregulation of many proinflammatory cytokines and chemokines. 1, 9 The IL-17R/Act1 complex also recruits TRAF2 and TRAF5 to prolong the half-life of CXCL1. 10 In contrast, TRAF3 has been reported to play a negative regulatory role in IL-17 signaling by interfering with the formation of the IL-17R-Act1-TRAF6 complex. 10, 11 Due to a broad role in driving inflammatory responses, IL-17 signaling should be under tight control to avoid harmful inflammation and autoimmune diseases. However, in contrast to studies on Th17 cells, there are far fewer studies focused on IL-17 downstream signaling, 12 particularly on whether and how IL-17 downstream signaling affects the development of autoimmune diseases.
Thousand and one kinase 1 (TAOK1), also known as prostate-derived sterile 20 (Ste20)-like kinase 2, TAO1 (thousand and one amino-acid protein 1) or MARKK, is a member of the MAP kinase kinase kinases and belongs to the germinal-center kinase-like class of sterile 20 (Ste20)-like kinases. 13, 14 TAOK1 can function as a regulator of microtubule dynamics and mitotic progression through interaction with a spindle checkpoint component. 15, 16 A recent study has reported that TAOK1 is a direct kinase for large tumor suppressor 1/2 of the Hippo pathway. 17 Furthermore, TAOK1 is involved in the activation of P38 and c-Jun NH2-terminal kinase (JNK) in response to DNA damage and stress stimuli. 18, 19 These reports provide insight into the potential role of TAOK1 in the MAPK signaling pathway.
In this study, we report that TAOK1 functions as a negative regulator in IL-17-mediated signaling and inflammation. TAOK1 inhibits the IL-17-induced expression of proinflammatory cytokines and chemokines. Furthermore, TAOK1 inhibits the IL-17-triggered activation of p38, JNK, extracellular signal-regulated kinase (ERK1/2) and p65 in HeLa cells. TAOK1 interacts with IL-17RA and inhibits the formation of the IL-17RA-Act1 complex in a kinase activity-independent manner, which results in the negative regulation of the IL-17-mediated inflammatory response. In addition, the expression of TAOK1 in the colon mucosal epithelia of ulcerative colitis (UC) patients is decreased. TAOK1-deficient mice are more sensitive to 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced IBD, suggesting that TAOK1 prevents TNBS-induced IBD.
MATERIALS AND METHODS
Mice TAOK1 fl/fl mice were obtained from Cyagen Biosciences Inc. (Suzhou, China). The mice were crossed with Pvillin-Cre transgenic mice to generate TAOK1 conditional knockout (KO) mice (Pvillin-cre +/ − TAOK1 fl/fl ) for the specific deletion of TAOK1 in intestinal epithelial cells (IECs). The mice were maintained and bred under pathogen-free conditions. All animal experimental procedures were carried out in accordance with protocols approved by the Scientific Investigation Board of Zhejiang University (Hangzhou, China).
Human samples
Paraffin-embedded human colon sections from UC patients were obtained from the Second Affiliated Hospital of Zhejiang Chinese Medical University (also called Xinhua Hospital). Control colon samples were obtained from the resection edges of tumor biopsies and appeared to be normal at the histological level. Detailed information from all patients, including sex, age and location, is shown in Table 1 .
Reagents and plasmids TNBS was purchased from Sigma (St Louis, MO, USA). Recombinant IL-17A (human) was purchased from Peprotech (Rocky Hill, NJ, USA). A human IL-6 ELISA Kit was obtained from eBioscience (San Diego, CA, USA). Phospho-antibodies against NF-κB p65, ERK, JNK and p38 and corresponding antibodies against total proteins were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-TRAF6 and anti-β actin were purchased from Santa Cruz (Santa Cruz, CA, USA). Anti-TAOK1 and anti-IL-17RA were purchased from Abcam Biotechnology (Cambridge, UK). Anti-HA, anti-DDK (Flag) and anti-Myc were obtained from Origene Technologies (Rockville, MD, USA). Horse radish peroxidase-coupled secondary antibodies were purchased from Cell Signaling Technology. pCMV6-TAOK1 and pCMV6-Act1 vectors expressing human TAOK1 and Act1 were purchased from Origene. Truncated TAOK1 was amplified from cDNA expressing fulllength TAOK1 and cloned into the pCMV6-Myc expression vector (Clontech Laboratories, Mountain View, CA, USA) to construct Myc-tagged TAOK1 expression plasmids. HA-IL-17RA was provided by Xiaojian Wang (Institute of Immunology, Zhejiang University).
Cell culture, plasmid transfection and siRNA silencing HeLa and HEK293T cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). HeLa cells were cultured in 1640 supplemented with 10% fetal bocine serum (FBS). HEK293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. The plasmids were transfected into HeLa and HEK293 cells with jetPEI (Polyplus, S.Brant. Illkirch, France) according to the manufacturer's protocols. 20 Control Non-target siRNA and TAOK1 on-target siRNA were obtained from Dharmacon (Thermo Fisher Scientific, Waltham, MA, USA). siRNA were transfected into HeLa cells with Lipofectamine RNAiMAX Quantitative real-time PCR and ELISA Total RNA was extracted with an RNA extraction kit, and cDNAs were synthesized using a cDNA synthesis kit (Takara) according to the manufacturer's instructions. 22 Real-time PCR was performed with a SYBR PCR kit (Takara) on an ABI PRISM ® 7900 Sequence Detection System (Applied Biosystems). The primers used are shown in Table 2 . The data were normalized to the gapdh or β-actin expression level in each sample. The production of IL-6 in the culture supernatants was detected using an ELISA Kit (eBioscience).
Co-immunoprecipitation and immunoblot analysis
Co-immunoprecipitation and immunoblotting were carried out as previously described. 23 Briefly, cells were lysed with cell lysis buffer supplemented with a cocktail of proteinase inhibitors (Cell Signaling Technology). Protein concentrations in the extracts were measured with the BCA assay (Thermo Fisher Scientific). Equal amounts of supernatants were incubated with specific antibodies and protein A/G Sepharose (sc-2003, Santa Cruz) for immunoprecipitation or loaded for SDS-polyacrylamide gel electrophoresis. Immunoblotting was performed using the indicated antibodies.
TNBS-induced colitis and histological analysis
The mice were presensitized with 1% (wt/vol) TNBS that was diluted in acetone and olive oil and applied to the abdomen of mice. Seven days later, the mice were rectally injected with TNBS (200 mg/kg) in 50% ethanol through a catheter inserted into the colon, as previously described. 24 Mice were sacrificed 4 days after the TNBS injection.
Mouse colon tissue was fixed in 10% formalin and embedded in paraffin. Cut tissues were stained with hematoxylin and eosin (H&E). Histological scores were assessed blindly using criteria that have been previously described. 25, 26 Briefly, 0 = no inflammation, 1 = moderate mucosal inflammation without erosion or ulceration, 2 = increased mucosal inflammation with erosion, 3 = increased mucosal inflammation with ulceration (o1 mm), and 4 = increased mucosal inflammation with ulceration (41 mm).
Disease activity index
The DAI score was measured by adding three separate scores, namely, body weight loss, presence of blood in stool, and the severity of diarrhea, as previously described. 25 Briefly, body weight loss score (0, none; 1, 1-5%; 2, 6-10%; 3, 11-20%; and 4, 420%), presence of blood in stool (0, no blood; 1, positive hemoccult; 2, visible blood traces in stool; 3, visible blood in stool and anal region; and 4, gross bleeding), and severity of diarrhea (0, normal stool; 1, soft stool; 2, soft and pasty stool; 3, soft and pasty stool that adhered to the anus; and 4, liquid stool). The DAI score was determined blindly during the colitis experiment.
Statistical analysis
The results are expressed as the mean ± standard deviation (s.d.). The significance of the difference between 2 groups was determined using Student's t-test analysis. The specimen analysis of UC patients was assessed using Pearson's chisquared tests with a 95% confidence interval (CI). A value Po0.05 was regarded as statistically significant.
RESULTS

TAOK1 knockdown promotes IL-17-induced inflammation
To evaluate the potential role of TAOK1 in IL-17 signaling, we analyzed the effect of TAOK1 knockdown on IL-17-induced cytokine and chemokine production in HeLa cells. TAOK1 protein expression was significantly decreased in HeLa cells transfected with small interfering RNA (siRNA) specifically targeting TAOK1 ( Figure 1a ). As shown in Figure 1b , TAOK1 knockdown remarkably upregulated the IL-17 induction of IL-6 protein secretion by HeLa cells. Moreover, in addition to increasing the IL-6 mRNA expression, IL-17 treatment markedly induced chemokine mRNA expression in HeLa cells, such as CXCL1, CXCL2, CCL20 and CSF3, and the induction of these cytokines and chemokines was substantially upregulated in TAOK1 knockdown cells (Figure 1c) . These results indicate that TAOK1 serves as a negative regulator of IL-17-induced proinflammatory cytokine and chemokine production in HeLa cells.
TAOK1 inhibits IL-17-induced NF-κB and MAPK activation
Upon IL-17 stimulation, the IL-17RA/RC complex recruits Act1 to trigger downstream signaling pathways, including the activation of MAPKs and NF-κB. 9, 27 To investigate the mechanism by which TAOK1 negatively regulates IL-17-mediated cytokine and chemokine production, we observed Human gapdh, reverse primer 5′-GGATCTCGCTCCTGCAAGATG-3′ Human il-6, forward primer 5′-ATGAACTCCTTCTCCACAAGCGC-3′ Human il-6, reverse primer 5′-GGGAAGGCAGCAGGCAACAC-3′ Human cxcl1, forward primer 5′-AGTCATAGCCACACTCAAGAATGG-3′ Human cxcl1, reverse primer 5′-GATGCAGGATTGAGGCAAGC-3′ Human cxcl2, forward primer 5′-CTCAAGAATGGGCAGAAAGC-3′ Human cxcl2, reverse primer 5′-AAACACATTAGGCGCAATCC-3′ Human ccl20, forward primer 5′-GCGCAAATCCAAAACAGACT-3′ Human ccl20, reverse primer 5′-CAAGTCCAGTGAGGCACAAA- 
TAOK1 associates with IL-17RA
To further investigate the underlying mechanisms by which TAOK1 inhibits IL-17 triggered signaling, HeLa cells overexpressing Myc-tagged TAOK1 were lysed to detect the target proteins of TAOK1 in the IL-17 signaling pathway. Main upstream signal regulators of IL-17 signaling, such as IL-17RA, Act1, TRAF6, TRAF2 and TRAF5, were detected in the immunoprecipitated complexes using an antibody against the Myc tag. 6, 28 The results showed that TAOK1 physically interacted with endogenous IL-17RA in resting HeLa cells, and the interaction was enhanced in response to IL-17 treatment (Figure 3a) . However, the association of TAOK1 with Act1, TRAF6, TRAF2 and TRAF5 was undetected. TAOK1 contains an N-terminal catalytic domain (CAT), a central substrate binding domain, a spacer and a tail domain. To investigate whether TAOK1 interacts with IL-17RA via its kinase catalytic activity, we constructed a kinase-inactive mutant TAOK1 K57A plasmid and N-terminal CAT-deleted (TAOK1-C) plasmid (Figure 3b) . Consistent with the results of the wild-type TAOK1, both TAOK1 K57A and TAOK1-C interacted with IL-17RA in HEK293T cells (Figure 3c ). Furthermore, similar to the results of the wild-type TAOK1, overexpression of TAOK1 K57A and TAOK1-C in HeLa cells downregulated IL-17-induced phosphorylation of NF-κB and MAPKs (Figure 3d ). Taken together, these data suggest that TAOK1 inhibits the IL-17 signaling pathway in a kinase activity-and CAT-independent manner.
TAOK1 inhibits the interaction between IL-17RA and Act1
Upon binding with IL-17, the IL-17RA/IL-17RC heterodimer recruits TRAF6 via the adaptor protein Act1 to activate downstream NF-κB and MAPK signaling and induce the production of proinflammatory cytokines and chemokines. 1 Considering that the association of TAOK1 with IL-17RA was enhanced in response to IL-17 treatment in HeLa cells, we investigated whether TAOK1 inhibits IL-17-mediated signaling via interfering with the interaction between IL-17RA and Act1. HEK293 cells were co-transfected with Flag-Act1, HA-IL-17RA and varying Figure 4a , co-immunoprecipitation analysis confirmed the interaction between ectopically expressed TAOK1 and IL--17RA, and TAOK1 dose-dependently inhibited the association between IL-17RA and Act1, as determined using an antibody to the HA tag. Similar results were obtained in a separate experiment following the same plasmid transfection and detection with an antibody to the Flag tag (Figure 4b ). These results suggest that TAOK1 might inhibit IL-17 signaling by downregulating the formation of the IL-17RA and Act1 complex.
TAOK1 inhibits colitis IL-17R signaling has been reported to promote the development of human IBD and augment IBD in the TNBS-induced mouse IBD model. 24, 29, 30 We collected a cohort of UC patient biopsies and normal control subject biopsies from the Xinhua Hospital of Zhejiang Province, China, and used the anti-TAOK1 antibody to detect TAOK1 expression in the colonic biopsies. Only 3.2% of the UC patient biopsies (1/31) exhibited strong TAOK1 staining, whereas more than 60% of the control subjects (62.1%, 18/29) showed strong TAOK1 staining (Po0.005) (Figure 5a ).
Immunohistochemical analysis showed that the TAOK1 protein expression level in IECs was markedly decreased in patients with UC compared with normal control subjects (Figure 5b ). These results collectively indicate that TAOK1 might be involved in the development of human colitis. We further investigated the role of TAOK1 in the TNBSinduced mouse IBD model. Pvillin-cre +/ − TAOK1 fl/fl (TAOK1 cKO) mice and control Pvillin-cre − / − TAOK1 fl/fl (wild-type (WT)) littermates were treated with TNBS as described previously. 24 Immunohistochemical analysis showed that TAOK1 protein expression was significantly decreased in the colonic epithelia of TAOK1 cKO mice (Figure 6a ). Compared with WT mice, TAOK1 cKO mice exhibited higher sensitivity to TNBS-induced colitis, which was demonstrated by greater weight loss (Figure 6b ) and a higher disease activity index (DAI) (Figure 6c ). TAOK1 cKO mice showed more severe colon shortening than WT mice (Figures 6d and e) . Histological analysis of the intestine showed that WT and TAOK1 cKO mice did not have obvious pathological signs under basal conditions. However, TNBS treatment revealed more severe epithelial damage and crypt disruption in TAOK1 cKO mice compared to WT mice (Figures 6f and g ). Consistent with these results, the were treated with IL-17 (50 ng/ml) for the indicated time. Phosphorylation and total NF-κB P65, P38, JNK and ERK and expression levels of TRAF6, TAOK1 and β-actin were detected by western blot. Numbers below lanes (top) indicate densitometry of the protein relative to β-actin expression in that same lane (below). Data are from one of three experiments with similar results. ERK, extracellular signal-regulated kinase; IL, interleukin; JNK, c-Jun N-terminal kinase; MAPK, mitogenactivated protein kinase; NF-κB, nuclear factor-κB; siRNA, small interfering RNA; TAOK1, thousand and one kinase 1; TRAF6, tumor necrosis factor receptor-associated factor 6.
TAOK1 inhibits IL-17 signaling Z Zhang et al amount of TNBS-induced mucosal proinflammatory cytokine and chemokine (IL-6, CXCL1 and CXCL2) expression in the colons of TAOK1 cKO mice was substantially higher than that of WT mice (Figure 6h ). These data demonstrate that the lack of TAOK1 in the intestine contributes to TNBS-induced colonic damage and colitis.
DISCUSSION IL-17 plays critical roles in the pathogenesis of various inflammatory responses and autoimmune disorders. Thus, precise regulation of IL-17-triggered signaling is needed to avoid harmful immunopathology. In this study, we examined the effect of TAOK1 on the IL-17 triggered inflammatory response. We showed that TAOK1 negatively regulates IL-17 signaling by inhibiting the formation of the IL-17RA and Act1 complex. IL-17 binds to the IL-17RA-IL-17RC heterodimer and induces IL-17R-Act1-TRAF6 complex formation, leading to cytokine and chemokine production. Owing to the contribution of excessive IL-17 to many inflammatory and autoimmune diseases, the development of new IL-17-based treatments that target steps in the signaling pathway is an attractive therapeutic strategy. TAOK1 inhibits IL-17 signaling Z Zhang et al TAOK1 can restrict cell proliferation by directly phosphorylating T195 to regulate Hippo-Salvador-Warts pathway signaling in developing imaginal epithelia. 31 As substrates of MST3, TAO kinases can regulate neuron dendritic filopodia and spine synapse development. 32 However, the role of TAOK1 in inflammation and other specific signaling pathways is still poorly understood. In this study, we identified TAOK1 as a negative regulator in IL-17-mediated inflammation in vitro and in vivo. TAOK1 knockdown significantly upregulated inflammatory gene expression induced by IL-17 treatment. The association of TAOK1 with endogenous IL-17RA was detected in resting cells, and the interaction was enhanced upon IL-17 treatment. Interestingly, overexpressed TAOK1, the kinase-inactive mutant K57A and the CAT-deleted plasmid TAOK1-C interacted with IL-17RA. IL-17 is involved in the pathogenesis of IBD. 33, 34 In addition to enhancing the IL-17-triggered response in vitro, TAOK1 deficiency also resulted in exacerbated inflammatory responses in TNBS-induced colitis in vivo.
Act1, 33,34 TRAF3, 10 TRAF6, 34 TRAF2 and TRAF5 35 have been demonstrated to be involved in the regulation of IL-17-mediated NF-κB and MAPK activation. In this study, we found that TAOK1 significantly inhibited the activation of NF-κB and MAPKs upon IL-17 stimulation, suggesting that TAOK1 is a negative regulator of IL-17R proximal signaling. Coimmunoprecipitation experiments demonstrated that TAOK1 interacted with IL-17RA and that the interaction was enhanced upon IL-17 treatment. Further results showed that TAOK1 negatively regulated IL-17-mediated signaling by inhibiting the formation of the IL-17RA-Act1 complex. TRAF3 has been reported to play a negative role in IL-17R-induced signaling. The binding of TRAF3 to IL-17R interfered with IL-17RA-Act1-TRAF6 complex formation, resulting in inhibition of downstream signaling. 10 The effect of TRAF3 on TAOK1-regulated IL-17 signaling needs to be further studied. Our findings show a previously unreported, novel function of TAOK1 in IL-17 signaling that is independent of its kinase activity. TAOK1 interacts with IL-17R and interferes with the formation of the IL-17RA and Act1 complex, which is required for downstream NF-κB and MAPK activation, leading to decreased proinflammatory factor production. TAOK1-deficient mice are more sensitive to TNBS-induced colitis, and TAOK1 expression was decreased in the colon tissue of UC patients. Our results demonstrate that TAOK1 is a negative regulator of IL-17 signaling and that it may have therapeutic utility as a target for the treatment of IL-17-associated inflammatory disorders.
